Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
30-Day DAPT in Patients at High Bleeding Risk Undergoing PCI With Biodegradable-Polymer Sirolimus-Eluting Ultra-Thin Stent.
Catheter Cardiovasc Interv
March 2025
Department of Cardiology, Maasstad Hospital, Rotterdam, the Netherlands.
Background: There is limited evidence on the safety and efficacy of biodegradable-polymer sirolimus-eluting ultra-thin stent (BP-SES) in patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI).
Aims: This study aims to evaluate the clinical outcomes of HBR patients treated with BP-SES and ≤ 30-day dual antiplatelet therapy (DAPT) regimen.
Methods: A systematic review was conducted to identify relevant studies involving HBR patients who underwent PCI with BP-SES (Supraflex Cruz).
Mechanical Thrombectomy for Cerebral Embolism after Transcatheter Aortic Valve Replacement: A Case Report.
J Neuroendovasc Ther
February 2025
Department of Neurosurgery, Nagoya Tokushukai General Hospital, Kasugai, Aichi, Japan.
Objective: Cerebral infarction is a major perioperative complication of transcatheter aortic valve replacement (TAVR). The number of patients undergoing TAVR has been increased annually. Therefore, neurosurgeons and neurologists who engage in stroke therapy, including mechanical thrombectomy (MT), may have more opportunities to treat stroke patients after TAVR in the future.
View Article and Find Full Text PDFRisk of cardiovascular diseases and gastrointestinal bleeding is comparable between celecoxib and non-selective non-steroidal anti-inflammatory drugs in patients with ankylosing spondylitis: a nationwide retrospective cohort study.
Scand J Rheumatol
March 2025
Department of Internal Medicine, Pusan National University School of Medicine, Yangsan, Republic of Korea.
Objective: To compare the risk of cardiovascular disease (CVD) and gastrointestinal bleeding (GIB) between celecoxib and non-selective non-steroidal anti-inflammatory drugs (nsNSAIDs) in patients with ankylosing spondylitis (AS).
Method: In this nationwide retrospective cohort study using the Korean Health Insurance Review and Assessment database, adult AS patients who received newly prescribed non-steroidal anti-inflammatory drugs (NSAIDs) continuously for ≥ 30 days (celecoxib or nsNSAIDs) between 2013 and 2017 were evaluated. The co-primary outcomes were the occurrence of composite CVD events, including hospitalization for myocardial infarction, ischaemic heart disease, stroke, transient ischaemic attack, heart failure, and coronary revascularization; and composite GIB, including hospitalization for upper and lower GIB.
Plaque shift to the brachiocephalic artery after subclavian artery stenting: illustrative case.
J Neurosurg Case Lessons
February 2025
1Department of Neurosurgery, Osaka Police Hospital, Osaka, Japan.
Background: Subclavian artery stenosis (SAS) has a prevalence of 1.9% in the general United States population. Revascularization, often by stenting, is indicated for symptomatic patients.
View Article and Find Full Text PDFTROPonin In CArotid Revascularisation - TROPICAR: Preliminary 30 Day Results.
Eur J Vasc Endovasc Surg
February 2025
Faculty of Medicine, University of Belgrade, Belgrade, Serbia; Clinic for Vascular and Endovascular Surgery, University Clinical Center of Serbia, Belgrade, Serbia. Electronic address:
Objective: To assess the prevalence and risk factors for the occurrence of myocardial injury (MIn) in patients undergoing carotid revascularisation and to assess whether elevated troponin levels can predict the occurrence of adverse cardiac events and short term mortality.
Methods: This prospective, multicentric cohort study included 527 patients subjected to carotid revascularisation from June to October 2023. High sensitive cardiac troponin I and/or T were assessed pre-operatively, and 8 and 24 hours post-operatively.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!